Tirzepatide 10 mg Results: 19.5% Mean Weight Loss in SURMOUNT-1
The 10 mg tirzepatide dose is one of the most-studied weight-loss intervention dosages in modern medicine — SURMOUNT-1 reported a 19.5% mean body weight reduction at 72 weeks.
Tirzepatide 10 mg weekly is the fourth step in the Zepbound titration (weeks 13-16) and one of the highest-performing weight-loss doses in any published obesity trial. SURMOUNT-1 NEJM 2022 (Jastreboff et al) reported 19.5% mean body weight reduction at 72 weeks on tirzepatide 10 mg — substantially more than semaglutide 2.4 mg's 14.9% in STEP 1. The 10 mg dose is FDA-approved as both a titration step toward 15 mg and as a long-term maintenance setpoint.
SURMOUNT-1 detailed outcomes at 10 mg
| Outcome | Tirzepatide 10 mg | Placebo |
|---|---|---|
| Mean weight loss (72 wks) | 19.5% | 3.1% |
| % losing ≥5% | 89% | 35% |
| % losing ≥10% | 71% | 14% |
| % losing ≥15% | 50% | 3% |
| % losing ≥20% | 31% | <1% |
For a 200 lb starting weight, 19.5% mean weight loss equals 39 lbs lost. 71% of 10 mg participants lost at least 20 lbs; 31% lost at least 40 lbs. These are among the strongest weight-loss outcomes ever produced in a randomized controlled trial — comparable to or exceeding some bariatric-surgery cohorts at 1-2 year follow-up.
Where 10 mg sits in clinical practice
Standard Zepbound titration: 2.5 mg (wks 1-4) → 5 mg (wks 5-8) → 7.5 mg (wks 9-12) → 10 mg (wks 13-16) → 12.5 mg (wks 17-20) → 15 mg (wks 21+ maintenance). Many real-world patients hold at 10 mg long-term — it's strong enough for substantial weight loss but produces fewer side effects than the 15 mg maximum.
Cardiovascular and metabolic outcomes at 10 mg
Beyond weight loss, SURMOUNT-1 reported significant improvements at 10 mg: systolic blood pressure −7.6 mm Hg, HbA1c −0.46% (in patients without diabetes), waist circumference −15.3 cm, fasting triglycerides −24.7%, fasting insulin −41.4%, hsCRP (inflammation marker) −37.3%. These metabolic improvements are clinically meaningful independent of weight loss.
Get to 10 mg tirzepatide with Trimi
$125/month annual plan covers full titration from 2.5 mg starter through 10 mg or 15 mg maintenance. Same active ingredient as Zepbound and Mounjaro.
Start your visitFAQs
What weight loss does 10 mg tirzepatide produce?
SURMOUNT-1 NEJM 2022 reported 19.5% mean body weight reduction at 72 weeks on tirzepatide 10 mg vs 3.1% on placebo. 89% of patients on 10 mg lost at least 5% of body weight; 71% lost ≥10%; 50% lost ≥15%. This is among the strongest weight-loss outcomes in any modern obesity-medicine trial.
When do I reach tirzepatide 10 mg?
Week 13 per the standard titration. After 2.5 mg (wks 1-4), 5 mg (wks 5-8), and 7.5 mg (wks 9-12), patients escalate to 10 mg in weeks 13-16. Some patients hold at 10 mg as maintenance; others continue escalating to 12.5 and 15 mg.
Is 10 mg enough or should I escalate to 15 mg?
Depends on individual response. SURMOUNT-1 data: 10 mg → 19.5% mean weight loss, 15 mg → 20.9%. The marginal benefit at higher doses is real but smaller per mg. Many patients hold at 10 mg long-term, especially if appetite suppression feels strong and side effects are manageable. Escalation to 15 mg is reasonable if you've plateaued at 10 mg and want additional loss.
Side effects at 10 mg tirzepatide?
From SURMOUNT-1 10 mg arm: nausea 33%, diarrhea 21%, vomiting 14%, constipation 17%, abdominal pain ~10%. Most are mild-to-moderate. Some patients experience the strongest GI symptoms at the 10 mg step before stabilizing. Severe symptoms warrant dropping back to 7.5 mg for 4 weeks before re-attempting.
Is 10 mg an FDA-approved maintenance dose?
Yes — Zepbound is FDA-approved at 5, 7.5, 10, 12.5, and 15 mg as either titration steps or long-term maintenance setpoints. 10 mg is a common real-world maintenance dose for patients who want strong therapeutic effect without pushing to the 15 mg maximum.
How fast will I lose weight at 10 mg?
Most patients on 10 mg lose 1-2 lbs per week during active titration weeks. Rate slows toward steady-state as caloric deficit stabilizes. Per SURMOUNT-1, mean weight loss continued through ~52 weeks before approaching plateau. Patients targeting >15% total body weight reduction typically reach goal within 72-100 weeks of continuous treatment.
Related reading
Disclaimer: Informational, not medical advice. Trial citation: Jastreboff AM et al, NEJM 2022 (SURMOUNT-1). Compounded tirzepatide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. **The FDA does not review or approve any compounded medications for safety or effectiveness.